Entries by Max

UPDATE: MRT-2359 Plus Apalutamide Combination Enters Phase 2 Trial for AR-Mutated Advanced Prostate Cancer

/in , , /by

A new phase 2 trial is evaluating MRT-2359 in combination with apalutamide for patients with androgen receptor (AR) mutation-positive metastatic castration-resistant prostate cancer, an advanced disease that may become resistant to standard hormone-directed treatments. The first patient has been dosed in the MODeFIRe-1 study, which plans to enroll up to 25 patients. Participants must have […]

Beyond PSA: Could ctDNA Become an Early Compass for Treatment in Metastatic Prostate Cancer?

/in /by

For decades, PSA has been the main biomarker used to monitor prostate cancer. It is inexpensive, accessible, and clinically familiar, but it does not always reflect what is happening inside metastatic tumors. PSA production is linked to androgen-receptor signaling, meaning that treatment-resistant or neuroendocrine-like tumor clones may continue to grow without producing a corresponding PSA […]

Soon to be Phase 1 Trial: AK157D1 a New B7‑H3–Targeted ADC in Advanced Prostate Cancer

/in , , /by

The investigational B7‑H3–targeting antibody–drug conjugate AK157D1, recently cleared for a Phase I trial in advanced solid tumors, is especially compelling from a prostate cancer perspective because B7‑H3 (CD276) is one of the most uniformly expressed and biologically aggressive surface targets across the full disease continuum, from hormone‑sensitive to castration‑resistant and neuroendocrine phenotypes. Unlike PSMA, which […]

Drug Combination Shows Promise Against Treatment-Resistant Prostate Cancer

/in , /by

A University of Michigan study suggests that combining two types of drugs could offer a new approach to treating advanced, treatment-resistant prostate cancer. The research focused on tumors that have changed their identity through a process called transdifferentiation. These tumors can become more aggressive and may no longer respond well to standard treatments that target […]

Newsletter 34/2026

/in /by

LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! Here we are again, with more news about the new weapons that are being developed. Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE.​ […]

How Prostate Cancer Hijacks Amino Acids to Beat Hormone Therapy

/in /by

Prostate cancer cells can outsmart hormone therapy by rewiring how they use nutrients, and a new preclinical study from Weill Cornell Medicine shows exactly how. Published in Nature Metabolism, the work reveals that tumors hijack the metabolism of two common amino acids, isoleucine and valine, to boost cholesterol production inside the tumor. That extra cholesterol […]

pTVG-HP DNA Vaccine Shows Long-Term Survival Benefit in Recurrent Prostate Cancer

/in , , /by

Long-term follow-up from a randomized phase 2 trial suggests that the DNA vaccine pTVG-HP (MVI-816) may significantly extend overall survival in men with PSA-recurrent, non-metastatic, castration-sensitive prostate cancer. The findings are particularly notable because the vaccine did not improve the study’s original primary endpoint of 2-year metastasis-free survival. The trial enrolled 99 men whose prostate […]

UPDATE: PGV001 Trial Focused on Prostate Cancer

/in , , /by

Mount Sinai is testing a personalized vaccine designed to help the immune system recognize and attack residual prostate-cancer cells. The phase 1 trial is evaluating PGV001, a multi-peptide vaccine created from each patient’s own tumor mutations, in combination with CDX-301, a cytokine intended to strengthen the immune response. Unlike a preventive vaccine, this is a […]

Phase 1/2 Trial for CRG-150, a New Approach to Immunotherapy

/in , , , /by

CRG-150 is entering first-in-human testing as an unconventional immunotherapy for patients with relapsed or refra9ctory metastatic prostate cancer and other solid tumors. The autologous, CRISPR-edited cell therapy targets steroid receptor coactivator 3, or SRC-3, in regulatory T cells. Tregs help maintain immune tolerance but can suppress antitumor immunity in prostate cancer. By disrupting SRC-3, CRG-150 […]

SCD1 Inhibition May Strengthen Enzalutamide Against Resistant Prostate Cancer

/in /by

SCD1 is an enzyme that helps prostate-cancer cells convert saturated fatty acids into monounsaturated fatty acids, which support cell membranes, energy storage and survival signaling. Functional research suggests that some tumors rely on SCD1 activity. Blocking this pathway can disrupt lipid synthesis, androgen-receptor signaling and survival pathways such as AKT. This provides the rationale for […]